Clinical Trial: Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional




Official Title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability,Immunogenicity, and Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccin

Brief Summary: The overall objective of the MEDI-534 clinical development program is to evaluate the safety, efficacy and tolerability of MEDI-534 for the prevention of serious RSV and PIV3 disease in young infants.